Nanosuspension: An Emerging Trend for Bioavailability Enhancement of Etodolac

Table 2

Drug content, percentage yield, particle Size (P.S.), and size distribution of nanosuspensions prepared by antisolvent method.

Formula code	Stabilizer	Drug content (%); antisolvent method	% Yield; antisolvent method	P.S. in nm	PdI^*
F1	Crude drug	—	—	3676 ± 42.6	0.52
F2	Nanosuspension without stabilizer	100	99.74	4234 ± 67.4	1.00
F11	Na CMC	92	85.77	464 ± 7.6	0.83
F12	HPMC	96.8	98.33	603 ± 5.9	0.78
F13	PVP K45	80.0	87.92	290 ± 6.8	0.85
F14	PVA	85.5	91.93	468 ± 9.1	0.85
F15	PEG 400	90.0	92.86	474 ± 6.2	0.78
F16	Tween 20	98.0	93.09	119 ± 4.6	0.79
F17	Tween 80	95.0	92.80	160 ± 3.9	0.54
F18	β-cyclodextrin	95.0	93.61	517 ± 7.4	0.78

PdI^*: polydispersibility index.